AstraZeneca details $2.5B investment in China's political center, funding R&D center, biotech pacts

AstraZeneca has shown its commitment to China amid investigations into its executives and activities, outlining plans to establish a global strategic R&D center in Beijing as part of a $2.5 billion investment in the city.